Increased serum calpain activity is associated with HMGB1 levels in systemic sclerosis.
Calpain
HMGB1
Interstitial lung disease
Microarray analysis
Systemic sclerosis
Journal
Arthritis research & therapy
ISSN: 1478-6362
Titre abrégé: Arthritis Res Ther
Pays: England
ID NLM: 101154438
Informations de publication
Date de publication:
11 05 2020
11 05 2020
Historique:
received:
03
03
2020
accepted:
23
04
2020
entrez:
13
5
2020
pubmed:
13
5
2020
medline:
17
6
2021
Statut:
epublish
Résumé
Systemic sclerosis (SSc) or scleroderma is an intractable autoimmune disorder that affects multiple organs. The objectives were to investigate clinical correlations of serum calpain activity and high mobility group box 1 (HMGB1) levels with immunological and clinical traits. A total of 31 patients with SSc, 20 age- and gender-matched healthy control subjects (HC), and 10 patients with other connective tissue diseases (CTD) were recruited in the study. We measured serum calpain activity and HMGB1 levels and analyzed the datasets (GSE40839, GSE48149, GSE76808, GSE81292, GSE33463, and GSE58095) from Gene Expression Omnibus (GEO) database to explore the potential mechanism by which calpain exerts its function through bioinformatics methods. Serum calpain activity was significantly increased in patients with SSc compared with those in HC and in patients with CTD and was correlated with serum HMGB1 levels, modified Rodnan skin score, erythrocyte sedimentation rate, mean platelet volume, and plateletcrit. Notably, serum calpain activity and HMGB1 levels in SSc patients with interstitial lung disease (ILD) were significantly higher than those in SSc patients without ILD. Serum calpain activity and HMGB1 levels could be the independent risk factors for SSc-ILD and novel biomarkers in patients with SSc. This is the first study that reports increased serum calpain activity and the correlation between calpain and HMGB1 in patients with SSc or SSc-ILD. The serum calpain activity and HMGB1 levels may serve as measures of ILD in patients with SSc. Also, calpain and HMGB1 could be potential therapeutic targets for patients with SSc or SSc-ILD in the future.
Sections du résumé
BACKGROUND
Systemic sclerosis (SSc) or scleroderma is an intractable autoimmune disorder that affects multiple organs. The objectives were to investigate clinical correlations of serum calpain activity and high mobility group box 1 (HMGB1) levels with immunological and clinical traits.
METHODS
A total of 31 patients with SSc, 20 age- and gender-matched healthy control subjects (HC), and 10 patients with other connective tissue diseases (CTD) were recruited in the study. We measured serum calpain activity and HMGB1 levels and analyzed the datasets (GSE40839, GSE48149, GSE76808, GSE81292, GSE33463, and GSE58095) from Gene Expression Omnibus (GEO) database to explore the potential mechanism by which calpain exerts its function through bioinformatics methods.
RESULTS
Serum calpain activity was significantly increased in patients with SSc compared with those in HC and in patients with CTD and was correlated with serum HMGB1 levels, modified Rodnan skin score, erythrocyte sedimentation rate, mean platelet volume, and plateletcrit. Notably, serum calpain activity and HMGB1 levels in SSc patients with interstitial lung disease (ILD) were significantly higher than those in SSc patients without ILD. Serum calpain activity and HMGB1 levels could be the independent risk factors for SSc-ILD and novel biomarkers in patients with SSc.
CONCLUSION
This is the first study that reports increased serum calpain activity and the correlation between calpain and HMGB1 in patients with SSc or SSc-ILD. The serum calpain activity and HMGB1 levels may serve as measures of ILD in patients with SSc. Also, calpain and HMGB1 could be potential therapeutic targets for patients with SSc or SSc-ILD in the future.
Identifiants
pubmed: 32393322
doi: 10.1186/s13075-020-02195-y
pii: 10.1186/s13075-020-02195-y
pmc: PMC7216546
doi:
Substances chimiques
Biomarkers
0
HMGB1 Protein
0
Calpain
EC 3.4.22.-
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
110Références
Ann Rheum Dis. 2017 May;76(5):924-934
pubmed: 28062404
Am J Respir Crit Care Med. 2020 Mar 15;201(6):650-660
pubmed: 31841044
J Postgrad Med. 2017 Oct-Dec;63(4):257-261
pubmed: 28862243
Lancet. 2017 Oct 7;390(10103):1685-1699
pubmed: 28413064
Clin Exp Immunol. 2010 Dec;162(3):560-7
pubmed: 20846163
Nat Rev Drug Discov. 2016 Dec;15(12):854-876
pubmed: 27833121
Diabetologia. 2019 May;62(5):860-872
pubmed: 30778623
Arthritis Rheum. 2008 Sep;58(9):2845-53
pubmed: 18759303
Blood. 1992 Nov 1;80(9):2246-51
pubmed: 1421394
Autoimmunity. 2014 Dec;47(8):487-93
pubmed: 24916843
Autoimmun Rev. 2017 Aug;16(8):774-786
pubmed: 28572048
Mediators Inflamm. 2017;2017:5230374
pubmed: 29200665
Diabetes. 2016 Jan;65(1):255-68
pubmed: 26470784
J Exp Med. 2015 Jan 12;212(1):5-14
pubmed: 25559892
Cardiovasc Res. 2013 Jun 1;98(3):381-90
pubmed: 23455548
J Atheroscler Thromb. 2018 Jan 1;25(1):1-15
pubmed: 28819082
Int J Mol Sci. 2019 Nov 24;20(23):
pubmed: 31771292
J Clin Immunol. 2009 Mar;29(2):180-9
pubmed: 18825489
Physiol Rev. 2003 Jul;83(3):731-801
pubmed: 12843408
Cardiovasc Res. 2012 Oct 1;96(1):38-45
pubmed: 22425901
Nat Rev Rheumatol. 2014 Dec;10(12):706-19
pubmed: 25136781
Am J Med. 1997 Sep;103(3):242-8
pubmed: 9316557
PLoS One. 2016 Aug 18;11(8):e0161436
pubmed: 27537498
Bioinformatics. 2010 Jun 15;26(12):1572-3
pubmed: 20427518
DNA Repair (Amst). 2019 Nov;83:102701
pubmed: 31563843
Semin Respir Crit Care Med. 2006 Dec;27(6):600-12
pubmed: 17195137
J Biol Chem. 2012 Aug 10;287(33):27480-9
pubmed: 22753411
J Clin Invest. 2007 Mar;117(3):557-67
pubmed: 17332883
Naunyn Schmiedebergs Arch Pharmacol. 2018 Jul;391(7):695-704
pubmed: 29666896
Sci Transl Med. 2018 Jul 25;10(451):
pubmed: 30045975
J Am Coll Cardiol. 2009 Apr 28;53(17):1573-619
pubmed: 19389575
Am J Transl Res. 2017 Mar 15;9(3):1402-1409
pubmed: 28386365
Biochim Biophys Acta. 2015 Sep;1852(9):1796-804
pubmed: 26071646
J Cell Sci. 2005 Sep 1;118(Pt 17):3829-38
pubmed: 16129881
Sci Transl Med. 2013 Jan 9;5(167):167sr1
pubmed: 23303606
ISRN Rheumatol. 2013 Sep 23;2013:835948
pubmed: 24175099
Nat Rev Rheumatol. 2018 Sep;14(9):499
pubmed: 30108366
Addict Biol. 2017 May;22(3):724-741
pubmed: 26857094
Autoimmunity. 2012 Dec;45(8):584-7
pubmed: 22928592
Aging (Albany NY). 2019 Jul 14;11(13):4338-4353
pubmed: 31303606
Circ Heart Fail. 2015 Sep;8(5):988-96
pubmed: 26246018
Pulm Pharmacol Ther. 2018 Feb;48:46-52
pubmed: 29107090
Brain Res Bull. 2017 Jun;132:139-149
pubmed: 28528202
Autoimmun Rev. 2018 Jun;17(6):625-635
pubmed: 29635077
Nature. 2002 Jul 11;418(6894):191-5
pubmed: 12110890
Ann Rheum Dis. 2013 Nov;72(11):1747-55
pubmed: 24092682
Semin Immunopathol. 2016 Jan;38(1):87-95
pubmed: 26577237